Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.2849
+0.00230.81%
Volume:694.87K
Turnover:197.79K
Market Cap:12.64M
PE:-0.17
High:0.2999
Open:0.2837
Low:0.2778
Close:0.2826
52wk High:5.14
52wk Low:0.1980
Shares:44.38M
Float Shares:41.42M
Volume Ratio:0.37
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6559
EPS(LYR):-1.8303
ROE:-166.46%
ROA:-83.21%
PB:0.52
PE(LYR):-0.16

Loading ...

Vistagen Says Fasedienol Misses Primary Endpoint in Palisade-4 Phase 3 Social Anxiety Trial

Reuters
·
Jun 30

Vistagen Announces Topline and Post-hoc Data from Palisade-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics - Plans to Meet with FDA on Registration Pathway for Fasedienol with Future Phase 3 Trial

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics Inc: Fasedienol Did not Achieve Statistically Significant Improvement on Primary and Secondary Endpoints

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics - Post-hoc Analysis Shows Nominal Statistical Significance for Fasedienol in Very Severe Social Anxiety Subgroup

THOMSON REUTERS
·
Jun 30

Vistagen Therapeutics Inc: Favorable Safety and Tolerability Data were Consistent with Previous Clinical Trials

THOMSON REUTERS
·
Jun 30

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Reuters
·
Jun 30

VistaGen directors FitzPatrick, Curley to step down after 2026 annual meeting

Reuters
·
Jun 18

Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth

TIPRANKS
·
Jun 17

VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate

Benzinga Earnings
·
Jun 16

VistaGen FY26 net loss widens to $69.7 million; R&D expense rises to $55 million

Reuters
·
Jun 16

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Jun 16

Vistagen Therapeutics Says Fasedienol Clinical Program Exceeds ICH Exposure Thresholds

MT Newswires Live
·
Jun 10

Vistagen announces fasedienol achieves minimum patient exposures

TIPRANKS
·
Jun 09

Vistagen Achieves Minimum Ich Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Jun 09

Vistagen Therapeutics - Topline Results From Palisade-4 Phase 3 Trial Expected in Q2 2026

THOMSON REUTERS
·
Jun 09

VistaGen says fasedienol SAD program meets ICH E1 minimum long-term safety exposure thresholds

Reuters
·
Jun 09

VistaGen to join Jefferies Global Healthcare Conference, hosts investor meetings

Reuters
·
May 27

VistaGen files initial beneficial ownership statement for Chief Medical Officer Angel S. Angelov

Reuters
·
May 20

BRIEF-Vistagen Appoints Angel S. Angelov As Chief Medical Officer

Reuters
·
May 19